They include trans-arterial embolization (TAE),

trans-arterial chemoembolization (TACE), radiofrequency thermal ablation. Newly developed locoregional ablative procedures are under evaluation. TAE is based on selective infusion of particles in the branch (segmental or subsegmental) of the hepatic artery supplying the tumor lesions. The goal of TAE is to occlude tumor blood vessels resulting in ischemia and necrosis. TACE differs from TAE for the administration of a chemotherapeutic agent (anthracyclines such as Doxorubicin or Epirobicin) mixed with Lipiodol (fat-soluble contrast-medium with high concentration of Iodine; Lipiodol R), into the hepatic artery followed by the administration selleckchem of embolizing agents (75-150 μm). In TAE treatment, Lipiodol

administration (50%) is followed by the administration of embolizing agents (75-150 μm) without the administration of chemotherapeutic agents. Eligible patients for these procedures include NEN patients in metastatic phase, with predominant liver disease, which is judjed not resectable by surgery [18, 19]. Although both techniques have been widely adopted, it remains debatable if the addition of cytotoxic drugs to embolization material increases the effectiveness of bland embolization alone, particularly when performed selectively [20, 21]. This review will focus Midostaurin ic50 on TAE in NEN patients with liver metastases. Clinical, biochemical, instrumental characterization of NEN patients before TAE Clinical work-up has to establish if the tumor is associated with a functioning endocrine syndrome which can result also in life-threatening conditions. Carcinoid syndrome is the most frequent functioning endocrine syndrome predominantly associated with the presence of liver metastases Resveratrol (60%). Regardless from endocrine symptoms, tumor mass-related symptoms need to be carefully evaluated, highlighting in particular the patient performance status, hepatic function

and degree of liver involvement by the tumor, as liver metastases are often multilocular and bilateral [22]. Plasma chromogranin A (CgA) should be measured in all cases in order to have a potential sensitive marker, helpful for tumor monitoring and follow-up. However false-positive CgA false positive need to be carefully excluded [23, 24]. The 24 h urinary 5-hydroxyindolacetic acid (5-HIAA) is an additional sensitive marker in NENs with carcinoid syndrome [25]. Other helpful NEN markers related to the specific syndrome are insulin, gastrin, glucagons or vasoactive intestinal polypeptide, to be evaluated according to the clinical picture [26, 27]. Contrast-enhanced abdominal ultrasound and multidetector-row computed tomography (CT) are the standard initial imaging procedures. Advanced CT protocols and fusioning CT – positron emission tomography (PET) showed a sensitivity of 94–100% [28, 29].